Real-world Evidence for the Safety of Oral JAK Inhibitors in Inflammatory Skin Diseases: A Systematic Review and Meta-analysis

Attachment 1_PRISMA 2020 checklist;
Attachment 2_Search strategy;
Attachment 3_List of excluded records and reason of exclusion;
Attachment 4_Assessment results of risk of bias;
Attachment 5_Result of Meta-analysis using the "PFT" method;
Attachment 6_Result of Meta-analysis using the "PRAW" method;